JP2015529635A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015529635A5 JP2015529635A5 JP2015520410A JP2015520410A JP2015529635A5 JP 2015529635 A5 JP2015529635 A5 JP 2015529635A5 JP 2015520410 A JP2015520410 A JP 2015520410A JP 2015520410 A JP2015520410 A JP 2015520410A JP 2015529635 A5 JP2015529635 A5 JP 2015529635A5
- Authority
- JP
- Japan
- Prior art keywords
- ube3a
- compound
- ats
- seq
- region
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 168
- 101000772888 Homo sapiens Ubiquitin-protein ligase E3A Proteins 0.000 claims description 114
- 102100030434 Ubiquitin-protein ligase E3A Human genes 0.000 claims description 114
- 108091060203 Ube3a-ATS Proteins 0.000 claims description 106
- 230000000692 anti-sense effect Effects 0.000 claims description 88
- 108091034117 Oligonucleotide Proteins 0.000 claims description 86
- 150000007523 nucleic acids Chemical group 0.000 claims description 62
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 60
- 230000000295 complement effect Effects 0.000 claims description 55
- 108020004999 messenger RNA Proteins 0.000 claims description 53
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 36
- 230000001939 inductive effect Effects 0.000 claims description 35
- 238000011144 upstream manufacturing Methods 0.000 claims description 26
- 230000008685 targeting Effects 0.000 claims description 21
- 239000002777 nucleoside Substances 0.000 claims description 12
- 150000003833 nucleoside derivatives Chemical class 0.000 claims description 8
- 125000004400 (C1-C12) alkyl group Chemical group 0.000 claims description 4
- LRSASMSXMSNRBT-UHFFFAOYSA-N 5-methylcytosine Chemical group CC1=CNC(=O)N=C1N LRSASMSXMSNRBT-UHFFFAOYSA-N 0.000 claims description 4
- 125000002619 bicyclic group Chemical group 0.000 claims description 4
- 125000003835 nucleoside group Chemical group 0.000 claims description 4
- 125000006239 protecting group Chemical group 0.000 claims description 4
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 claims description 4
- 208000009575 Angelman syndrome Diseases 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 238000004132 cross linking Methods 0.000 claims 1
- 230000008775 paternal effect Effects 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 238000000034 method Methods 0.000 description 155
- 210000004027 cell Anatomy 0.000 description 29
- 241001465754 Metazoa Species 0.000 description 28
- 108020003224 Small Nucleolar RNA Proteins 0.000 description 13
- 102000042773 Small Nucleolar RNA Human genes 0.000 description 13
- 108091030111 Small nucleolar RNA SNORD115 Proteins 0.000 description 7
- 230000003834 intracellular effect Effects 0.000 description 3
- 108091032955 Bacterial small RNA Proteins 0.000 description 2
- 102000007999 Nuclear Proteins Human genes 0.000 description 2
- 108010089610 Nuclear Proteins Proteins 0.000 description 2
- 108091033400 Small nucleolar RNA SNORD116 Proteins 0.000 description 2
- 101150069235 Snrpn gene Proteins 0.000 description 2
- 210000004748 cultured cell Anatomy 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261664083P | 2012-06-25 | 2012-06-25 | |
| US61/664,083 | 2012-06-25 | ||
| US201261738959P | 2012-12-18 | 2012-12-18 | |
| US61/738,959 | 2012-12-18 | ||
| US201361750939P | 2013-01-10 | 2013-01-10 | |
| US61/750,939 | 2013-01-10 | ||
| US201361755617P | 2013-01-23 | 2013-01-23 | |
| US61/755,617 | 2013-01-23 | ||
| US201361772925P | 2013-03-05 | 2013-03-05 | |
| US61/772,925 | 2013-03-05 | ||
| PCT/US2013/047701 WO2014004572A2 (en) | 2012-06-25 | 2013-06-25 | Modulation of ube3a-ats expression |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015529635A JP2015529635A (ja) | 2015-10-08 |
| JP2015529635A5 true JP2015529635A5 (OSRAM) | 2016-08-12 |
| JP6294876B2 JP6294876B2 (ja) | 2018-03-14 |
Family
ID=49784000
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015520410A Active JP6294876B2 (ja) | 2012-06-25 | 2013-06-25 | Ｕｂｅ３ａ−ａｔｓ発現の調節 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US9617539B2 (OSRAM) |
| EP (4) | EP2864479B1 (OSRAM) |
| JP (1) | JP6294876B2 (OSRAM) |
| AU (1) | AU2013280474B2 (OSRAM) |
| CA (1) | CA2877905A1 (OSRAM) |
| DK (2) | DK2864479T3 (OSRAM) |
| ES (3) | ES2987225T3 (OSRAM) |
| HU (1) | HUE051698T2 (OSRAM) |
| LT (1) | LT3461895T (OSRAM) |
| PL (1) | PL3461895T3 (OSRAM) |
| PT (1) | PT3461895T (OSRAM) |
| SI (1) | SI3461895T1 (OSRAM) |
| WO (1) | WO2014004572A2 (OSRAM) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2864479B1 (en) | 2012-06-25 | 2018-08-15 | Ionis Pharmaceuticals, Inc. | Modulation of ube3a-ats expression |
| US10400243B2 (en) | 2014-11-25 | 2019-09-03 | Ionis Pharmaceuticals, Inc. | Modulation of UBE3A-ATS expression |
| HUE062186T2 (hu) | 2015-05-07 | 2023-09-28 | Univ South Florida | Módosított UBE3A gén az Angelman-szindróma génterápiás megközelítésére |
| MA67580B1 (fr) | 2015-11-12 | 2024-09-30 | F. Hoffmann-La Roche Ag | Oligonucléotides pour induire l'expression de paternal ube3a |
| AU2017368050A1 (en) | 2016-11-29 | 2019-06-20 | Puretech Lyt, Inc. | Exosomes for delivery of therapeutic agents |
| AU2018375807B2 (en) * | 2017-12-01 | 2025-04-10 | The Texas A&M University System | Angelman syndrome antisense treatment |
| CN111770758A (zh) * | 2018-02-27 | 2020-10-13 | 北卡罗来纳-查佩尔山大学 | 用于治疗Angelman综合征的方法和组合物 |
| US10704048B2 (en) | 2018-06-14 | 2020-07-07 | Ovid Therapeutics Inc. | Use of MIR-92A or MIR-145 in the treatment of Angelman syndrome |
| AU2019344006B2 (en) * | 2018-09-21 | 2025-11-27 | University Of Connecticut | Compositions and methods to restore paternal UBE3A gene expression in human Angelman Syndrome |
| CN113316722A (zh) * | 2019-01-17 | 2021-08-27 | 豪夫迈·罗氏有限公司 | E3泛素连接酶(ube3a)蛋白质靶标 |
| CR20210538A (es) | 2019-03-29 | 2021-12-06 | Ionis Pharmaceuticals Inc | Compuestos y métodos para modular ube3a-ats |
| EA202193214A1 (ru) * | 2019-05-22 | 2022-03-14 | Дзе Юниверсити Оф Норт Каролина Эт Чепел Хилл | Гены ube3a и кассеты экспрессии и их использование |
| WO2021011802A1 (en) * | 2019-07-16 | 2021-01-21 | The University Of North Carolina At Chapel Hill | Methods and compositions for unsilencing imprinted genes |
| GB201912103D0 (en) * | 2019-08-22 | 2019-10-09 | Univ Oxford Innovation Ltd | Method of haplotyping |
| EP4076471A4 (en) | 2019-12-18 | 2023-12-27 | National University of Singapore | Method for treating angelman syndrome and related disorders |
| US20230167438A1 (en) * | 2020-04-28 | 2023-06-01 | The Trustees Of The University Of Pennsylvania | Compositions and uses thereof for treatment of angelman syndrome |
| EP4288538A2 (en) * | 2021-02-03 | 2023-12-13 | The Board Of Regents Of The University Of Texas System | Gene therapy for angelman syndrome |
| US20240240179A1 (en) * | 2021-05-05 | 2024-07-18 | The General Hospital Corporation | Therapy for treatment of prader-willi syndrome |
| WO2023168000A1 (en) * | 2022-03-03 | 2023-09-07 | The Regents Of The University Of California | Compositions and methods for treatment of angelman syndrome |
| WO2025101991A1 (en) * | 2023-11-09 | 2025-05-15 | Ionis Pharmaceuticals, Inc. | Methods for modulating ube3a-ats |
| WO2025101533A1 (en) * | 2023-11-09 | 2025-05-15 | Encoded Therapeutics, Inc. | Methods and compositions for increasing expression of ube3a |
| WO2025217466A1 (en) * | 2024-04-11 | 2025-10-16 | Ultragenyx Pharmaceutical Inc. | Dosing regimens for antisense treatment of angelman syndrome |
Family Cites Families (83)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2699808A (en) | 1944-10-06 | 1955-01-18 | Mark W Lowe | Apparatus for peeling tomatoes |
| US2699508A (en) | 1951-12-21 | 1955-01-11 | Selectronics Inc | Method of mounting and construction of mounting for low frequency piezoelectric crystals |
| US5118800A (en) | 1983-12-20 | 1992-06-02 | California Institute Of Technology | Oligonucleotides possessing a primary amino group in the terminal nucleotide |
| FR2567892B1 (fr) | 1984-07-19 | 1989-02-17 | Centre Nat Rech Scient | Nouveaux oligonucleotides, leur procede de preparation et leurs applications comme mediateurs dans le developpement des effets des interferons |
| US5185444A (en) | 1985-03-15 | 1993-02-09 | Anti-Gene Deveopment Group | Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages |
| US5506337A (en) | 1985-03-15 | 1996-04-09 | Antivirals Inc. | Morpholino-subunit combinatorial library and method |
| US5166315A (en) | 1989-12-20 | 1992-11-24 | Anti-Gene Development Group | Sequence-specific binding polymers for duplex nucleic acids |
| US5034506A (en) | 1985-03-15 | 1991-07-23 | Anti-Gene Development Group | Uncharged morpholino-based polymers having achiral intersubunit linkages |
| US5591722A (en) | 1989-09-15 | 1997-01-07 | Southern Research Institute | 2'-deoxy-4'-thioribonucleosides and their antiviral activity |
| DE69034150T2 (de) | 1989-10-24 | 2005-08-25 | Isis Pharmaceuticals, Inc., Carlsbad | 2'-Modifizierte Oligonukleotide |
| US5670633A (en) | 1990-01-11 | 1997-09-23 | Isis Pharmaceuticals, Inc. | Sugar modified oligonucleotides that detect and modulate gene expression |
| US5646265A (en) | 1990-01-11 | 1997-07-08 | Isis Pharmceuticals, Inc. | Process for the preparation of 2'-O-alkyl purine phosphoramidites |
| GB9009980D0 (en) | 1990-05-03 | 1990-06-27 | Amersham Int Plc | Phosphoramidite derivatives,their preparation and the use thereof in the incorporation of reporter groups on synthetic oligonucleotides |
| DK0455905T3 (da) | 1990-05-11 | 1998-12-07 | Microprobe Corp | Dipsticks til nukleinsyrehybridiseringsassays og fremgangsmåde til kovalent immobilisering af oligonukleotider |
| US6582908B2 (en) | 1990-12-06 | 2003-06-24 | Affymetrix, Inc. | Oligonucleotides |
| EP0538194B1 (de) | 1991-10-17 | 1997-06-04 | Novartis AG | Bicyclische Nukleoside, Oligonukleotide, Verfahren zu deren Herstellung und Zwischenprodukte |
| US5359044A (en) | 1991-12-13 | 1994-10-25 | Isis Pharmaceuticals | Cyclobutyl oligonucleotide surrogates |
| FR2687679B1 (fr) | 1992-02-05 | 1994-10-28 | Centre Nat Rech Scient | Oligothionucleotides. |
| EP0577558A2 (de) | 1992-07-01 | 1994-01-05 | Ciba-Geigy Ag | Carbocyclische Nukleoside mit bicyclischen Ringen, Oligonukleotide daraus, Verfahren zu deren Herstellung, deren Verwendung und Zwischenproduckte |
| JPH08504559A (ja) | 1992-12-14 | 1996-05-14 | ハネウエル・インコーポレーテッド | 個別に制御される冗長巻線を有するモータシステム |
| ES2107205T3 (es) | 1993-03-30 | 1997-11-16 | Sanofi Sa | Analogos de nucleosidos aciclicos y secuencias oligonucleotidas que los contienen. |
| US5801154A (en) | 1993-10-18 | 1998-09-01 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of multidrug resistance-associated protein |
| US5446137B1 (en) | 1993-12-09 | 1998-10-06 | Behringwerke Ag | Oligonucleotides containing 4'-substituted nucleotides |
| US5519134A (en) | 1994-01-11 | 1996-05-21 | Isis Pharmaceuticals, Inc. | Pyrrolidine-containing monomers and oligomers |
| US5627053A (en) | 1994-03-29 | 1997-05-06 | Ribozyme Pharmaceuticals, Inc. | 2'deoxy-2'-alkylnucleotide containing nucleic acid |
| US5597909A (en) | 1994-08-25 | 1997-01-28 | Chiron Corporation | Polynucleotide reagents containing modified deoxyribose moieties, and associated methods of synthesis and use |
| US5656408A (en) | 1996-04-29 | 1997-08-12 | Xerox Corporation | Coated carrier particles |
| JP3756313B2 (ja) | 1997-03-07 | 2006-03-15 | 武 今西 | 新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体 |
| US6770748B2 (en) | 1997-03-07 | 2004-08-03 | Takeshi Imanishi | Bicyclonucleoside and oligonucleotide analogue |
| US6617162B2 (en) | 2001-12-18 | 2003-09-09 | Isis Pharmaceuticals, Inc. | Antisense modulation of estrogen receptor alpha expression |
| US6794499B2 (en) | 1997-09-12 | 2004-09-21 | Exiqon A/S | Oligonucleotide analogues |
| AU9063398A (en) | 1997-09-12 | 1999-04-05 | Exiqon A/S | Oligonucleotide analogues |
| US6238921B1 (en) * | 1998-03-26 | 2001-05-29 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of human mdm2 expression |
| US20030228597A1 (en) | 1998-04-13 | 2003-12-11 | Cowsert Lex M. | Identification of genetic targets for modulation by oligonucleotides and generation of oligonucleotides for gene modulation |
| US6043352A (en) | 1998-08-07 | 2000-03-28 | Isis Pharmaceuticals, Inc. | 2'-O-Dimethylaminoethyloxyethyl-modified oligonucleotides |
| KR20010112944A (ko) | 1999-04-21 | 2001-12-22 | 이곤 이 버그 | 폴리뉴클레오티드 서열의 기능을 억제하기 위한 방법 및조성물 |
| AU776362B2 (en) | 1999-05-04 | 2004-09-09 | Roche Innovation Center Copenhagen A/S | L-ribo-LNA analogues |
| US6525191B1 (en) | 1999-05-11 | 2003-02-25 | Kanda S. Ramasamy | Conformationally constrained L-nucleosides |
| US6300132B1 (en) | 1999-12-17 | 2001-10-09 | Isis Pharmaceuticals, Inc. | Antisense inhibition of telomeric repeat binding factor 2 expression |
| AU2698301A (en) | 1999-12-30 | 2001-07-16 | K.U. Leuven Research And Development | Cyclohexene nucleic acids |
| WO2001092582A1 (en) * | 2000-06-01 | 2001-12-06 | Genaissance Pharmaceuticals, Inc. | Haplotypes of the ube3a gene |
| US20030087855A1 (en) | 2001-09-13 | 2003-05-08 | Isis Pharmaceuticals Inc. | Antisense modulation of protein kinase R expression |
| EP1499627A2 (en) | 2001-07-03 | 2005-01-26 | ISIS Pharmaceuticals, Inc. | Nuclease resistant chimeric oligonucleotides |
| EP1578927A2 (en) | 2002-08-14 | 2005-09-28 | Pharmacia Corporation | Antisense modulation of nav1.3 expression |
| WO2004035765A2 (en) | 2002-10-18 | 2004-04-29 | Nucleonics, Inc. | Double-stranded rna structures and constructs, and methods for generating and using the same |
| EP2957568B1 (en) | 2002-11-05 | 2016-12-21 | Ionis Pharmaceuticals, Inc. | Compositions comprising alternating 2'-modified nucleosides for use in gene modulation |
| AU2003291753B2 (en) | 2002-11-05 | 2010-07-08 | Isis Pharmaceuticals, Inc. | Polycyclic sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation |
| EP2213738B1 (en) | 2002-11-14 | 2012-10-10 | Dharmacon, Inc. | siRNA molecules targeting Bcl-2 |
| US6673661B1 (en) | 2002-12-20 | 2004-01-06 | Taiwan Semiconductor Manufacturing Co., Ltd. | Self-aligned method for forming dual gate thin film transistor (TFT) device |
| WO2004106356A1 (en) | 2003-05-27 | 2004-12-09 | Syddansk Universitet | Functionalized nucleotide derivatives |
| ATE555118T1 (de) | 2003-08-28 | 2012-05-15 | Takeshi Imanishi | Neue synthetische nukleidsäuren vom typ mit quervernetzter n-o-bindung |
| JP5379347B2 (ja) | 2003-09-18 | 2013-12-25 | アイシス ファーマシューティカルズ， インコーポレーテッド | ４’−チオヌクレオシドおよびオリゴマー化合物 |
| CA2569419A1 (en) | 2004-06-03 | 2005-12-22 | Isis Pharmaceuticals, Inc. | Double strand compositions comprising differentially modified strands for use in gene modulation |
| WO2006047842A2 (en) | 2004-11-08 | 2006-05-11 | K.U. Leuven Research And Development | Modified nucleosides for rna interference |
| EP1764108A1 (en) * | 2005-09-14 | 2007-03-21 | Gunther Hartmann | Compositions comprising immunostimulatory RNA oligonucleotides and methods for producing said RNA oligonucleotides |
| JP5713377B2 (ja) | 2005-12-28 | 2015-05-07 | ザ スクリプス リサーチ インスティテュート | 薬物標的としての天然アンチセンスおよび非コードｒｎａ転写物 |
| US7825099B2 (en) * | 2006-01-20 | 2010-11-02 | Quark Pharmaceuticals, Inc. | Treatment or prevention of oto-pathologies by inhibition of pro-apoptotic genes |
| EP1984381B1 (en) | 2006-01-27 | 2010-09-29 | Isis Pharmaceuticals, Inc. | 6-modified bicyclic nucleic acid analogs |
| ES2389737T3 (es) | 2006-05-11 | 2012-10-31 | Isis Pharmaceuticals, Inc. | Análogos de ácidos nucleicos bicíclicos modificados en 5' |
| EP2125852B1 (en) | 2007-02-15 | 2016-04-06 | Ionis Pharmaceuticals, Inc. | 5'-substituted-2'-f modified nucleosides and oligomeric compounds prepared therefrom |
| US8278425B2 (en) | 2007-05-30 | 2012-10-02 | Isis Pharmaceuticals, Inc. | N-substituted-aminomethylene bridged bicyclic nucleic acid analogs |
| DK2173760T4 (en) | 2007-06-08 | 2016-02-08 | Isis Pharmaceuticals Inc | Carbocyclic bicyclic nukleinsyreanaloge |
| US8278283B2 (en) | 2007-07-05 | 2012-10-02 | Isis Pharmaceuticals, Inc. | 6-disubstituted or unsaturated bicyclic nucleic acid analogs |
| US8546556B2 (en) | 2007-11-21 | 2013-10-01 | Isis Pharmaceuticals, Inc | Carbocyclic alpha-L-bicyclic nucleic acid analogs |
| EP2265627A2 (en) | 2008-02-07 | 2010-12-29 | Isis Pharmaceuticals, Inc. | Bicyclic cyclohexitol nucleic acid analogs |
| WO2010036698A1 (en) | 2008-09-24 | 2010-04-01 | Isis Pharmaceuticals, Inc. | Substituted alpha-l-bicyclic nucleosides |
| EP2361256B1 (en) | 2008-09-24 | 2013-04-10 | Isis Pharmaceuticals, Inc. | Cyclohexenyl nucleic acid analogs |
| AT507215B1 (de) | 2009-01-14 | 2010-03-15 | Boehler Edelstahl Gmbh & Co Kg | Verschleissbeständiger werkstoff |
| EP2462153B1 (en) | 2009-08-06 | 2015-07-29 | Isis Pharmaceuticals, Inc. | Bicyclic cyclohexose nucleic acid analogs |
| NO2516648T3 (OSRAM) | 2009-12-23 | 2018-04-07 | ||
| WO2011109398A2 (en) * | 2010-03-02 | 2011-09-09 | President And Fellows Of Harvard College | Methods and compositions for treatment of angelman syndrome and autism spectrum disorders |
| JP6005628B2 (ja) | 2010-04-28 | 2016-10-12 | アイオーニス ファーマシューティカルズ， インコーポレーテッドＩｏｎｉｓ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． | 修飾ヌクレオシド、その類似体、およびこれらから調製されるオリゴマー化合物 |
| JP5998131B2 (ja) | 2010-07-14 | 2016-09-28 | カッパーアールエヌエー，インコーポレイテッド | Ｄｉｓｃｓｌａｒｇｅｈｏｍｏｌｏｇ（ｄｌｇ）ｄｌｇ１への天然アンチセンス転写物の阻害によるｄｌｇ関連疾患の治療 |
| AU2011282217B2 (en) * | 2010-07-19 | 2015-12-03 | Ionis Pharmaceuticals, Inc. | Modulation of dystrophia myotonica-protein kinase (DMPK) expression |
| WO2012064806A2 (en) * | 2010-11-11 | 2012-05-18 | The University Of North Carolina At Chapel Hill | Methods and compositions for unsilencing imprinted genes |
| EP3521451A1 (en) | 2010-11-17 | 2019-08-07 | Ionis Pharmaceuticals, Inc. | Modulation of alpha synuclein expression |
| US20140315992A1 (en) | 2011-07-07 | 2014-10-23 | The Children's Hospital Of Philadelphia | Genetic Alterations Associated with Autism and the Autistic Phenotype and Methods of Use Thereof for the Diagnosis and Treatment of Autism |
| EP2751270B1 (en) | 2011-08-29 | 2018-08-22 | Ionis Pharmaceuticals, Inc. | Oligomer-conjugate complexes and their use |
| US9984408B1 (en) | 2012-05-30 | 2018-05-29 | Amazon Technologies, Inc. | Method, medium, and system for live video cooperative shopping |
| EP2864479B1 (en) | 2012-06-25 | 2018-08-15 | Ionis Pharmaceuticals, Inc. | Modulation of ube3a-ats expression |
| MA67580B1 (fr) | 2015-11-12 | 2024-09-30 | F. Hoffmann-La Roche Ag | Oligonucléotides pour induire l'expression de paternal ube3a |
| US9778708B1 (en) | 2016-07-18 | 2017-10-03 | Lenovo Enterprise Solutions (Singapore) Pte. Ltd. | Dual sided latching retainer for computer modules |
| CR20210538A (es) | 2019-03-29 | 2021-12-06 | Ionis Pharmaceuticals Inc | Compuestos y métodos para modular ube3a-ats |
-
2013
- 2013-06-25 EP EP13809694.6A patent/EP2864479B1/en not_active Revoked
- 2013-06-25 EP EP20182895.1A patent/EP3770258B1/en active Active
- 2013-06-25 CA CA2877905A patent/CA2877905A1/en active Pending
- 2013-06-25 AU AU2013280474A patent/AU2013280474B2/en active Active
- 2013-06-25 DK DK13809694.6T patent/DK2864479T3/en active
- 2013-06-25 LT LTEP18188705.0T patent/LT3461895T/lt unknown
- 2013-06-25 PT PT181887050T patent/PT3461895T/pt unknown
- 2013-06-25 DK DK18188705.0T patent/DK3461895T3/da active
- 2013-06-25 PL PL18188705T patent/PL3461895T3/pl unknown
- 2013-06-25 EP EP24188665.4A patent/EP4458361A3/en active Pending
- 2013-06-25 EP EP18188705.0A patent/EP3461895B1/en not_active Revoked
- 2013-06-25 SI SI201331770T patent/SI3461895T1/sl unknown
- 2013-06-25 HU HUE18188705A patent/HUE051698T2/hu unknown
- 2013-06-25 WO PCT/US2013/047701 patent/WO2014004572A2/en not_active Ceased
- 2013-06-25 ES ES20182895T patent/ES2987225T3/es active Active
- 2013-06-25 ES ES18188705T patent/ES2809199T3/es active Active
- 2013-06-25 JP JP2015520410A patent/JP6294876B2/ja active Active
- 2013-06-25 ES ES13809694.6T patent/ES2688831T3/es active Active
- 2013-06-25 US US14/409,348 patent/US9617539B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015529635A5 (OSRAM) | ||
| JP4718379B2 (ja) | 修飾された低分子干渉ｒｎａ分子および使用方法 | |
| JP6294876B2 (ja) | Ｕｂｅ３ａ−ａｔｓ発現の調節 | |
| Pasternak et al. | Unlocked nucleic acid–an RNA modification with broad potential | |
| JP2019518037A (ja) | Ｂ型肝炎感染症治療用のＰＡＰＤ５又はＰＡＰＤ７のｍＲＮＡ減少用核酸分子 | |
| HRP20241138T1 (hr) | Oligonukleotidi za induciranje ekspresije očinskog ube3a | |
| JP2016513976A5 (OSRAM) | ||
| JP2008523094A5 (OSRAM) | ||
| JP2016522674A5 (OSRAM) | ||
| JP2015502365A5 (OSRAM) | ||
| RS60230B1 (sr) | Kompozicije za moduliranje ekspresije c9orf72 | |
| JP7667074B2 (ja) | Ｄｕｘ４の発現を調節するための化合物、方法及び医薬組成物 | |
| JP2012136542A5 (OSRAM) | ||
| JP2018507711A5 (OSRAM) | ||
| RU2014121304A (ru) | Ингибирование экспрессии вирусных генов | |
| CA3214439A1 (en) | Compositions and methods for inhibiting ketohexokinase (khk) | |
| WO2010006973A3 (en) | Compositions and methods for inhibiting expression of tgf-beta receptor genes | |
| HRP20191883T1 (hr) | Modulacija ekspresije tmprss6 | |
| Bhomia et al. | Artificial microRNAs can effectively inhibit replication of Venezuelan equine encephalitis virus | |
| US20210290653A1 (en) | Modulation of lnc05 expression | |
| Wu et al. | Cardiac miR-19a/19b was induced and hijacked by CVB3 to facilitate virus replication via targeting viral genomic RdRp-encoding region | |
| Kumar et al. | Sequence-specific cleavage of BM2 gene transcript of influenza B virus by 10-23 catalytic motif containing DNA enzymes significantly inhibits viral RNA translation and replication | |
| Bohle et al. | Species specific inhibition of viral replication using dicer substrate siRNAs (DsiRNAs) targeting the viral nucleoprotein of the fish pathogenic rhabdovirus viral hemorrhagic septicemia virus (VHSV) | |
| Du et al. | Effective inhibition of foot-and-mouth disease virus (FMDV) replication in vitro by vector-delivered microRNAs targeting the 3D gene | |
| WO2021211928A1 (en) | Compositions and methods of inhibiting severe acute respiratory syndrome coronavirus 2 (sars-cov-2) |